erlotinib hydrochloride has been researched along with thiourea in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (thiourea) | Trials (thiourea) | Recent Studies (post-2010) (thiourea) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,959 | 46 | 1,737 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | thiourea (IC50) |
|---|---|---|---|
| Urease | Canavalia ensiformis (jack bean) | 0.56 | |
| Serine-protein kinase ATM | Homo sapiens (human) | 0.2 | |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bearss, D; Cooke, LS; Croce, KD; Mahadevan, D; Qi, W; Riley, C; Saldanha, JW; Stejskal, A | 1 |
| Hu, Y; Tang, JF; Wang, XL; Yang, W; Yang, YS; Zhang, F; Zhang, YB; Zhong, WQ; Zhu, HL | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L | 1 |
| Cooke, LS; Kurtzman, D; Mahadevan, D; Morales, C; Ong, E; Qi, W; Stejskal, AE; Swart, R; Theiss, N; Zhu, M | 1 |
| Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL | 1 |
5 other study(ies) available for erlotinib hydrochloride and thiourea
| Article | Year |
|---|---|
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, SCID; Multigene Family; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiourea | 2009 |
Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Humans; MCF-7 Cells; Molecular Conformation; Molecular Docking Simulation; Naphthalenes; Protein Structure, Tertiary; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2013 |
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A | 2014 |
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Topics: Afatinib; Aged; Aged, 80 and over; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Thiourea | 2015 |
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2016 |